QUVIVIQ is a global product, delivering restorative nights and revitalized days to thousands of patients living with insomnia. Each market where QUVIVIQ is available presents its own opportunities and challenges. We must break down the barriers to prescription wherever we find them, to unlock the full value of QUVIVIQ for patients, healthcare providers, and the company. Furthermore, our teams must proactively profile the safety and efficacy of daridorexant in specific patient populations, giving physicians all the information they need to make their prescribing decisions.
QUVIVIQ
Unlocking the full value of QUVIVIQ
“Commercial efforts with QUVIVIQ, Europe’s first and only dual orexin receptor antagonist, are beginning to translate into promising success.”
— Benjamin Limal, President of EUCAN region
Partners
Expand strategic partnerships
Partner-led Portfolio
“Over the last few years, we have engaged in several important strategic partnerships. We often retain a vested interest in the success of our partnered products, which means that our alliances are of increasing importance to the company.”
— Julien Gander, Chief Legal & Corporate Development Officer
Idorsia engages in strong strategic partnerships, tapping into external resources to realize our objective of changing the treatment paradigm in underserved disorders. Whether such alliances are designed to support new discoveries, develop our compounds, or commercialize our products, we aim to be proactive and contribute to their success wherever possible. As the inventors of the assets – with expert knowledge of the wealth of data created and the evidence of efficacy and safety – we have a unique perspective to share when analyzing, interpreting, and describing the science and benefits. We will engage with and support our partners so as to maximize the value of our innovation.
Pipeline
Advance our differentiated pipeline assets
The company has completed a portfolio prioritization to advance four investigational clinical assets with the potential to transform treatment paradigms.
Lucerastat which has the potential to address a significant unmet medical need for patients with Fabry disease. We are actively engaging with regulators to optimize the path to approval based on recent biopsy data and long-term efficacy and safety results from the open-label study.
Idorsia will also advance three first-in-class chemokine receptor antagonists into studies which will each be proof-of-concept in the specific indication under investigation as well as proof-of-mechanism for a range of disorders where the pathways can be applied.
“We have an exciting and very unique early-stage clinical pipeline of potential transformative therapies that have come from our drug discovery group. We intend to develop these to the next inflection point before finding a partner.”
— Alberto Gimona, Executive Vice President, Head of Global Clinical Development
Idorsia-led Portfolio
Finance
Operate with financial discipline
We need to balance our ambition with accountability to our goal of sustainable profitability. Operating expenses will be managed by adjusting the company’s activities sufficiently to ensure that the funding will sustain Idorsia as we move towards profitability.
“The excellent performance from QUVIVIQ, particularly in Europe, puts us on-track to reach our improved financial guidance provided in May 2025 and overall profitability starting from the end of 2027.”
— Arno Groenewoud, Chief Financial Officer
Financial information
Read our latest financial reports and updates on how we will achieve sustainable profitability.
Our Innovation
Innovating from the lab bench all the way through to the patient’s bedside. Learn more about how we innovate, our portfolio and our target diseases.
Latest news
Our innovation is the basis for our long-term sustainability. Read the latest news from across our portfolio.
People
Empower our people to achieve excellence
Our science is only impactful because of the expertise, passion, and commitment of our people. Working in a lean, entrepreneurial environment can be challenging, but it also creates space for creativity and growth.
“I am consistently struck by the talent and commitment of our people – they are our greatest asset, united by a shared purpose and focused on delivering long-term value for allour stakeholders.”
— Srishti Gupta, CEO
More joy –
The spark of passion
We want our employees to feel proud of their work, and of the company they work for. We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
